Trials / Terminated
TerminatedNCT01391130
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2510924 | Administered subcutaneously |
| DRUG | Sunitinib | Administered orally |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2014-09-01
- Completion
- 2017-02-01
- First posted
- 2011-07-11
- Last updated
- 2019-07-23
- Results posted
- 2019-07-23
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01391130. Inclusion in this directory is not an endorsement.